A lab drug slows glioblastoma cells that resist treatment
Original title: KDM1A/HDAC2-driven epigenetic dysregulation maintains a drug-resistant, relapse-initiating glioblastoma cell niche at the peri-tumoral margin.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done in lab cells and gene data, not in people.
The short version
In lab dishes, a new drug slowed brain tumor cells that no longer respond to chemo.
What was studied. Researchers tested a drug called MPT0G521 on glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary cells grown in the lab. They also studied gene data from tumor samples to see which cells are hardest to treat.
What they found. The gene data pointed to two proteins, KDM1A and HDAC2, in fast-growing tumor cells. These cells sat at the edge of the tumor, where it often comes back. In lab dishes, the drug slowed growth in normal tumor cells and in cells that resist the chemo drug temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary. It stopped the cells from dividing and caused them to die.
What this means, and what it doesn't
What it could mean: This points to a possible new way to go after tumor cells that survive current treatment. It is an early idea that scientists can keep testing.
What it doesn't mean: This does not mean a new treatment is coming soon. The work was done in cells in the lab, not in people. No one knows yet if it is safe or if it helps patients live longer. It is not a treatment you can ask your doctor for, and it is not a cure.
Source: PubMed, September 2, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.